121 related articles for article (PubMed ID: 35972853)
1. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
[TBL] [Abstract][Full Text] [Related]
2. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
[TBL] [Abstract][Full Text] [Related]
3. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
4. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
[TBL] [Abstract][Full Text] [Related]
6. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
[TBL] [Abstract][Full Text] [Related]
7. Oral preexposure prophylaxis uptake, adherence, and persistence during periconception periods among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; Haberer JE; Baeten JM; Hendrix CW; Ware NC; Moodley P; Pillay M; Bennett K; Bassler J; Psaros C; Hurwitz KE; Bangsberg DR; Smit JA
AIDS; 2024 Jul; 38(9):1342-1354. PubMed ID: 38752557
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
[TBL] [Abstract][Full Text] [Related]
9. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
10. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
11. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
[TBL] [Abstract][Full Text] [Related]
12. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
13. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
Donnell D; Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Rees H; Baeten JM;
Lancet HIV; 2021 Aug; 8(8):e495-e501. PubMed ID: 34126052
[TBL] [Abstract][Full Text] [Related]
14. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
[TBL] [Abstract][Full Text] [Related]
15. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
[TBL] [Abstract][Full Text] [Related]
18. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
[TBL] [Abstract][Full Text] [Related]
19. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.
Joseph Davey D; Nyemba DC; Castillo-Mancilla J; Wiesner L; Norman J; Mvududu R; Mashele N; Johnson LF; Bekker LG; Gorbach P; Coates TJ; Myer L
J Int AIDS Soc; 2022 Dec; 25(12):e26044. PubMed ID: 36480171
[TBL] [Abstract][Full Text] [Related]
20. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
